ProCE Banner Activity

PRADO: Phase II Trial of Response-Directed Surgery and Adjuvant Therapy Following Neoadjuvant Ipilimumab and Nivolumab in Stage III Melanoma

Slideset Download
Conference Coverage
PRADO confirmed high pathologic response rates with neoadjuvant ipilimumab + nivolumab in stage III melanoma and demonstrated good outcomes in patients with major pathologic responses not receiving therapeutic lymph node dissection and adjuvant therapy

Released: June 13, 2022

Expiration: June 12, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab